Heart Attack Diagnostics Market Size, Share & Trends Analysis Report By Test (Electrocardiogram, Blood Test), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, )- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Heart Attack Diagnostics Market Size and Growth Report, 2033

The global heart attack diagnostics market size was valued at USD 11.18 billion in 2023 and is anticipated to reach around USD 25.05 billion by 2033, growing at a CAGR of 8.4% from 2024 to 2033.

Heart Attack Diagnostics Market Size, 2024 to 2033

Heart Attack Diagnostics Market Key Takeaways

  • North America emerged as the largest global heart attack diagnostics market, with a 38.45% share in 2023
  • The heart attack diagnostics market in Asia Pacific is projected to witness a steady CAGR of 10.0% during the forecast period.
  • In 2023, the blood tests segment emerged as the market leader, capturing the largest revenue share of 54.19%.
  • The electrocardiogram segment is anticipated to exhibit a CAGR of 7.2% from 2024 to 2033
  • The CK-MB (creatine kinase-myoglobin binding) segment in the blood tests category is expected to grow rapidly at a CAGR of 9.6% over the forecast period.  
  • The hospital segment accounted for a share of 21.35% in 2023
  • The ambulatory segment is expected to grow at a CAGR of 10.6% during forecast period.

The Unhealthy lifestyle choices, such as poor dietary habits, tobacco smoking, high body mass index, sedentary lifestyles, and the prevalence of chronic diseases such as diabetes and hypertension, are the primary risk factors contributing to the development of heart attacks in individuals.

The occurrence of a heart attack, or myocardial infarction, arises when specific regions of the heart muscle experience a lack of oxygen supply. This situation occurs due to the obstruction of blood flow to the heart muscle.

The COVID-19 pandemic adversely affected diagnosis and treatment of non-communicable diseases. The pandemic caused widespread disruptions in healthcare systems worldwide. Fear of contracting COVID-19 led many people to avoid seeking medical attention for potential medical attack symptoms.

According to the World Heart Report, cardiovascular diseases continue to affect more than 500 million people across the globe. Alarmingly, these diseases claimed the lives of 20.5 million individuals in 2021, accounting for nearly a third of all deaths worldwide. This represents a substantial increase compared to the estimated 121 million deaths attributed to cardiovascular diseases (CVDs). It impacts the heart and blood vessels, and their occurrence can be attributed to a combination of socio-economic, metabolic, behavioral, and environmental risk factors. These risk factors encompass high blood pressure, an unhealthy diet, elevated cholesterol levels, diabetes, air pollution, obesity, tobacco usage, kidney disease, physical inactivity, excessive alcohol consumption, and stress.

Heart Attack Diagnostics Market Report Scope

Report Attribute Details
Market Size in 2024 USD 12.12 Billion
Market Size by 2033 USD 25.05 Billion
Growth Rate From 2024 to 2033 CAGR of 8.4%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Test, end use, region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled GE Healthcare; Hitachi Corporation; Koninklijke Philips NV; Midmark Corporation; F Hoffmann-La Roche Ltd; Schiller AG; Siemens Healthineers; Toshiba Corporation; Welch Allyn Inc; Astrazenca PLC

U.S. Heart Attack Diagnostics Market Size, Industry Report, 2033

The U.S. heart attack diagnostics Market is valued at USD 3.01 Billion in 2023 and is projected to reach a value of USD 6.84 Billion by 2033 at a CAGR (Compound Annual Growth Rate) of 8.6% between 2024 and 2033.

U.S. Heart Attack Diagnostics Market Size, 2024 to 2033

North America emerged as the largest global heart attack diagnostics market, with a 38.45% share in 2023 pertaining to the rise of cardiovascular cases in Canada and the U.S. Other factors that play a key role in market development include advanced healthcare infrastructure and increased investments in innovation.

U.S. Heart Attack Diagnostics Market Trends

The U.S. heart attack diagnostics market is expected to witness a significant growth of CAGR 8.2% during the forecast period. Recent research conducted by the U.S. Centers for Disease Control (CDC) indicates that every 40 seconds, a person in the U.S. undergoes a heart attack, making it the most expensive medical treatment in American healthcare facilities. The American Heart Association forecasts that around 45% of the U.S. population will be impacted by heart diseases by 2035, largely due to factors such as obesity, smoking, and sedentary lifestyles, all of which can increase the risk of heart attacks and other cardiovascular complications.

Heart Attack Diagnostics Market Share, By Region, 2023 (%)

Europe Heart Attack Diagnostics Market Trends

The Europe heart attack diagnostics market, with a valuation of 3.1 billion, is expected to witness a growth rate of 7.4% during the forecast period from 2024 to 2030.  The increase in patients with coronary artery disease and peripheral artery diseases has contributed to this growth. The European Union reported on March 21, 2022, that cardiovascular attacks were a leading cause of death in the EU. Additionally, advancements in technology are incorporating portability features into testing devices, which is driving market revenue growth.

The heart attack diagnostics market in UK is projected to witness steady growth rate in forecast period owing to an ageing and growing population and improved survival rates. Furthermore, the country’s development in research and technology is pushing the market.

Germany heat attack diagnostics market is expected to experience growth in the coming years. Germany is one of the top countries in terms of mortality rates from heart attacks. Cardiovascular diseases are the leading cause of death in the Germany.  In addition, they are associated with significant health consequences for the individual and result in high medical costs for society.

Asia Pacific Heart Attack Diagnostics Market Trends

The heart attack diagnostics market in Asia Pacific is projected to witness a steady CAGR of 10.0% during the forecast period. Few regions experience a heavy burden of heart diseases, due to a large patient population in countries such as India and China.

The China heart attack diagnostics market is expected to witness a strong growth rate during the forecast period, 2024-2033. A recent report from Biospectrum reveals that China has a staggering population of around 290 million individuals affected by cardiovascular disease (CVD). CVD, encompassing stroke and ischemic heart disease (including heart attacks), stands as the primary cause of mortality in China, responsible for nearly two-fifths of all deaths. Notably, ischemic heart disease is rapidly emerging as the leading cause of premature death in the country.

Heart Attack Diagnostics Market Test Insights

In 2023, the blood tests segment emerged as the market leader, capturing the largest revenue share of 54.19%. One of the key factors driving the demand for blood tests in heart attack diagnostics is Troponin T, a protein found in heart muscle. Health care professionals utilize high-sensitivity troponin T tests to diagnose heart attacks and assess the risk of heart disease. Interestingly, even individuals without symptoms can have an increased level of troponin T, indicating a higher risk of heart disease. Other contributing factors include elevated cholesterol levels, the growing consumption of alcohol and tobacco, and the prevalence of unhealthy lifestyles among people.  

The electrocardiogram segment is anticipated to exhibit a CAGR of 7.2% from 2024 to 2033, owing to factors such as the growing elderly population, unhealthy lifestyles, and the increase in tobacco and alcohol use. Additionally, the progress in technology and the heightened emphasis on healthcare in emerging nations such as India and China could create additional investment and research prospects, potentially impacting the worldwide ECG market.

The Troponin segment dominated the blood tests market and accounted for a share of 62.5% in 2023.  Troponin T, a protein present in the heart muscle, is crucial in diagnosing heart attacks through a high-sensitivity troponin T test. This test is usually conducted when there are suspicions of heart muscle damage or during critical medical situations like heart attacks. Factors that can contribute to increased troponin levels include rapid heartbeat, high blood pressure in the lungs, and blockages in lung arteries due to blood clots, fat, or tumor cells.

The CK-MB (creatine kinase-myoglobin binding) segment in the blood tests category is expected to grow rapidly at a CAGR of 9.6% over the forecast period.  The CK-MB test is utilized to determine the level of creatine kinase in the bloodstream. This specific enzyme is predominantly found in the heart, with minor amounts also present in the skeletal muscles.

Heart Attack Diagnostics Market End-use Insights

The hospital segment accounted for a share of 21.35% in 2023 primarily attributed to the extensive surgical procedures carried out in hospital settings and the widespread penetration of hospitals globally. Each year, over 290,000 adults in the U.S. experience in-hospital cardiac arrests.

Heart Attack Diagnostics Market Share, By End-use , 2023 (%)

The ambulatory segment is expected to grow at a CAGR of 10.6% during forecast period. There is an increasing emphasis on expediting and enhancing the convenience of diagnosis, especially for non-critical cases. Moreover, the progress in medical technology is driving the creation of portable and user-friendly diagnostic tools.

Heart Attack Diagnostics Market Top Key Companies:

  • GE Healthcare
  • Hitachi Corporation
  • Koninklijke Philips NV
  • Midmark Corporation
  • F Hoffmann-La Roche Ltd
  • Schiller AG
  • Siemens Healthineers
  • Toshiba Corporation
  • Welch Allyn Inc
  • Astrazenca PLC

Heart Attack Diagnostics Market Recent Developments

  • In June 2024, Philips announced the launch of Philips Cardiac Workstation aims to transform diagnostic cardiology with introduction of new Cardiac Workstation, to enhance cardiology patients care and accelerate clinical decision making in Middle East and Africa (MEA) and Europe
  • In April 2024, GE Healthcare introduced Caption AI on Vscan Air SL to expand cardiac care access by allowing more clinicians/medical professional capture diagnostic-quality cardiac images.

Heart Attack Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Heart Attack Diagnostics market.

By Test 

  • Electrocardiogram
  • Blood Test
    • Troponin
    • CK-MB
  • Others

By End-use

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                    1.3. Research Methodology
                        1.3.1. Information Procurement
                        1.3.2. Information or Data Analysis
                        1.3.3. Market Formulation & Data Visualization
                        1.3.4. Data Validation & Publishing
                    1.4. Research Scope and Assumptions
                        1.4.1. List of Data Sources
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Heart Attack Diagnostics Market Variables, Trends, & Scope
                    3.1. Market Introduction/Lineage Outlook
                    3.2. Market Size and Growth Prospects (USD Billion)
                    3.3. Market Dynamics
                        3.3.1. Market Drivers Analysis
                        3.3.2. Market Restraints Analysis
                    3.4. Heart Attack Diagnostics Market Analysis Tools
                        3.4.1. Porter’s Analysis
                            3.4.1.1. Bargaining power of the suppliers
                            3.4.1.2. Bargaining power of the buyers
                            3.4.1.3. Threats of substitution
                            3.4.1.4. Threats from new entrants
                            3.4.1.5. Competitive rivalry
                        3.4.2. PESTEL Analysis
                            3.4.2.1. Political landscape
                            3.4.2.2. Economic and Social landscape
                            3.4.2.3. Technological landscape
                            3.4.2.4. Environmental landscape
                            3.4.2.5. Legal landscape
Chapter 4. Heart Attack Diagnostics Market: Test Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. Heart Attack Diagnostics Market: Test Movement Analysis, 2023 & 2030 (USD Billion)
                    4.3. Electrocardiogram
                        4.3.1. Electrocardiogram Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    4.4. Blood Test
                        4.4.1. Blood Test Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                            4.4.1.1. Troponin
                                4.4.1.1.1. Troponin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                            4.4.1.2. CK-MB
                                4.4.1.2.1. CK-MB Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    4.5. Others
                        4.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. Heart Attack Diagnostics Market: End Use Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. Heart Attack Diagnostics Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
                    5.3. Hospitals
                        5.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    5.4. Ambulatory Surgical Centers
                        5.4.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    5.5. Others
                        5.5.1. Others Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. Heart Attack Diagnostics Market: Regional Estimates & Trend Analysis
                    6.1. Heart Attack Diagnostics Market Share, By Region, 2023 & 2030, USD Billion
                    6.2. North America
                        6.2.1. North America Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.2.2. U.S.
                            6.2.2.1. U.S. Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.2.3. Canada
                            6.2.3.1. Canada Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.2.4. Mexico
                            6.2.4.1. Mexico Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    6.3. Europe
                        6.3.1. Europe Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.2. U.K.
                            6.3.2.1. U.K. Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.3. Germany
                            6.3.3.1. Germany Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.4. France
                            6.3.4.1. France Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.5. Italy
                            6.3.5.1. Italy Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.6. Spain
                            6.3.6.1. Spain Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.7. Denmark
                            6.3.7.1. Denmark Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.8. Norway
                            6.3.8.1. Norway Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.3.9. Sweden
                            6.3.9.1. Sweden Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    6.4. Asia Pacific
                        6.4.1. Asia Pacific Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.4.2. China
                            6.4.2.1. China Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.4.3. Japan
                            6.4.3.1. Japan Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.4.4. India
                            6.4.4.1. India Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.4.5. South Korea
                            6.4.5.1. South Korea Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.4.6. Australia
                            6.4.6.1. Australia Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.4.7. Thailand
                            6.4.7.1. Thailand Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    6.5. Latin America
                        6.5.1. Latin America Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.5.2. Brazil
                            6.5.2.1. Brazil Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.5.3. Argentina
                            6.5.3.1. Argentina Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                    6.6. Middle East and Africa
                        6.6.1. Middle East and Africa Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.6.2. Saudi Arabia
                            6.6.2.1. Saudi Arabia Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.6.3. UAE
                            6.6.3.1. UAE Heart Attack Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
                        6.6.4. South Africa
                            6.6.4.1. South Africa Heart Attack Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
                        6.6.5. Kuwait
                            6.6.5.1. Kuwait Heart Attack Diagnostics Market Estimates and Forecasts, 2017 - 2030 (USD Billion)
Chapter 7. Competitive Landscape
                    7.1. Recent Developments & Impact Analysis by Key Market Participants
                    7.2. Company Categorization
                    7.3. Company Heat Map Analysis
                    7.4. Company Profiles
                        7.4.1. GE Healthcare
                            7.4.1.1. Participant’s Overview
                            7.4.1.2. Financial Performance
                            7.4.1.3. Product Benchmarking
                            7.4.1.4. Recent Developments/ Strategic Initiatives
                        7.4.2. Hitachi Corporation
                            7.4.2.1. Participant’s Overview
                            7.4.2.2. Financial Performance
                            7.4.2.3. Product Benchmarking
                            7.4.2.4. Recent Developments/ Strategic Initiatives
                        7.4.3. Koninklijke Philips NV
                            7.4.3.1. Participant’s Overview
                            7.4.3.2. Financial Performance
                            7.4.3.3. Product Benchmarking
                            7.4.3.4. Recent Developments/ Strategic Initiatives
                        7.4.4. Midmark Corporation
                            7.4.4.1. Participant’s Overview
                            7.4.4.2. Financial Performance
                            7.4.4.3. Product Benchmarking
                            7.4.4.4. Recent Developments/ Strategic Initiatives
                        7.4.5. F Hoffmann-La Roche Ltd
                            7.4.5.1. Participant’s Overview
                            7.4.5.2. Financial Performance
                            7.4.5.3. Product Benchmarking
                            7.4.5.4. Recent Developments/ Strategic Initiatives
                        7.4.6. Schiller AG
                            7.4.6.1. Participant’s Overview
                            7.4.6.2. Financial Performance
                            7.4.6.3. Product Benchmarking
                            7.4.6.4. Recent Developments/ Strategic Initiatives
                        7.4.7. Siemens Healthineers
                            7.4.7.1. Participant’s Overview
                            7.4.7.2. Financial Performance
                            7.4.7.3. Product Benchmarking
                            7.4.7.4. Recent Developments/ Strategic Initiatives
                        7.4.8. Toshiba Corporation
                            7.4.8.1. Participant’s Overview
                            7.4.8.2. Financial Performance
                            7.4.8.3. Product Benchmarking
                            7.4.8.4. Recent Developments/ Strategic Initiatives
                        7.4.9. Welch Allyn Inc
                            7.4.9.1. Participant’s Overview
                            7.4.9.2. Financial Performance
                            7.4.9.3. Product Benchmarking
                            7.4.9.4. Recent Developments/ Strategic Initiatives
                        7.4.10. Astrazaneca PLC
                            7.4.10.1. Participant’s Overview
                            7.4.10.2. Financial Performance
                            7.4.10.3. Product Benchmarking
                            7.4.10.4. Recent Developments/ Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers